autoimmune
-
Shocking! Nearly $1 billion in sales, the blockbuster autoimmune drug Baricitinib’s compound patent and crystal form patent have both been declared invalid in China
DrugTimes will continue to follow up and report in a timely manner
-
Brain penetrating JAK1/TYK2 inhibitors for inflammation, autoimmune and CNS diseases
If you are looking for brain-penetrating JAK1/TYK2 inhibitors, please contact DrugTimes BD Team at BD@drugtimes.cn asap
-
First! FDA approves new indication for Johnson & Johnson’s IL-23 antibody
Congratulations to Johnson & Johnson!
-
The biggest biotech financing of the year has been born! Who will be the next “buyer”?
What will be the fate of this new player in autoimmune diseases in the future?
-
Celine Dion, the legendary pop diva, is waiting for a CAR-T therapy?
All our best wishes! We will continue to provide our assistance to drug discovery and development with full effort
-
Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field
DrugTimes will present more reports timely. Please stay tuned
-
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Congratulations to Lilly and Morphic! This acquisition will expand Lilly’s immunology pipeline with oral integrin therapies
-
【Product for Sale】Innovative Biological Product for Systemic Lupus Erythematosus (SLE)
If interested in this asset, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
